Nanoparticle-based delivery of small interfering RNA: Challenges for cancer therapy

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 3637-3657

  Miele, Evelina ^a   Spinelli, Gian Paolo ^b   Miele, Ermanno ^c   Fabrizio, Enzo Di ^c,d   Ferretti, Elisabetta ^b   Tomao, Silverio ^b   Gulino, Alberto ^a,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Biological barriers; Cancer therapy; Clinical trials; Delivery strategies; Nanoparticles; Small interfering RNA

Indexed keywords

AGN 211745; ALN RSV 01; ATU 027; BEVASIRANIB; CALAA 01; CATIONIC LIPID; CATIONIC POLYMER; I 5NP; LIGAND CONJUGATED SMALL INTERFERING RNA; LIGAND TARGETED SMALL INTERFERING RNA; LIPID; LIPOSOME; MICRORNA; MICROSPHERE; MIPOMERSEN; NAKED SMALL INTERFERING RNA; NANOPARTICLE; NEUTRAL NANOLIPOSOME; PLACEBO; POLYMER; PRO 040201; QPI 1007; QUANTUM DOT; RANIBIZUMAB; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SYL 1001; TD 101; TKM 080301; UNCLASSIFIED DRUG; UNINDEXED DRUG;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ACUTE KIDNEY FAILURE; ADVANCED CANCER; ANTERIOR ISCHEMIC OPTIC NEUROPATHY; ARTICLE; BREAST METASTASIS; CANCER GENE THERAPY; CHEMICAL MODIFICATION; COLORECTAL CANCER; CONGENITAL PACHYONYCHIA; DELAYED GRAFT FUNCTION; DIABETIC MACULAR EDEMA; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSPORT; DRY EYE; EYE PAIN; GENE DELIVERY SYSTEM; GENE REPRESSION; GENE VECTOR; HUMAN; HUMORAL IMMUNITY; HYPERCHOLESTEROLEMIA; IMMUNOSTIMULATION; INNATE IMMUNITY; KIDNEY CLEARANCE; KIDNEY INJURY; LIVER METASTASIS; MOLECULAR DYNAMICS; NANOTECHNOLOGY; NEOPLASM; NEUROBLASTOMA; NONHUMAN; OFF TARGET EFFECT; OPTIC NERVE ATROPHY; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTTRANSCRIPTIONAL GENE SILENCING; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETINA MACULA AGE RELATED DEGENERATION; RNA INTERFERENCE; STOMACH CANCER; SUBRETINAL NEOVASCULARIZATION; TUMOR MICROENVIRONMENT;

ANIMALS; DRUG DELIVERY SYSTEMS; GENETIC THERAPY; HUMANS; NANOPARTICLES; NEOPLASMS; RNA, SMALL INTERFERING;

EID: 84870369929     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S23696     Document Type: Article

References (168)

1. Druker B, Guilhot F, O'Brian S, etal. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417.
2. Goldenberg MM. Trastuzumab, a recombinant DNA derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999;2:309-318.
3. Peterson C. Drug therapy of cancer. Eur J Clin Pharmacol. 2011;67:437-447.
4. Gilbert W. The RNA world. Nature. 1986;319:216.
5. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806-811.
6. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494-498.
7. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA. Gene expression: RNA interference in adult mice. Nature. 2002;418:38-39.
8. Wall NR, Shi Y. Small RNA: can RNA interference be exploited for therapy? Lancet. 2003;362:1401-1403.
9. Devi GR. siRNA-based approaches in cancer therapy. Cancer Gene Ther. 2006;13:819-829.
10. Abdelrahim M, Safe S, Baker C, Abudayyeh C. RNAi and cancer: implications and applications. J RNAi Gene Silencing. 2006;2:136-145.
11. Gartel AL, Kandel ES. RNA interference in cancer. Biomol Eng. 2006;23:17-34.
12. Grimm D, Kay MA. RNAi and gene therapy: a mutual attraction. Hematol Am Soc Hematol Educ Program. 2007:473-481.
13. DeVincenzo J, Lambkin-Williams R, Wilkinson T, etal. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2010;107:8800-8805.
14. Subramanya S, Kim SS, Manjunath N, Shankar P. RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA? Expert Opin Biol Ther. 2010;2:201-213.
15. Chen Y, Cheng G, Mahato RI. RNAi for treating hepatitis B viral infection. Pharm Res. 2008;1:72-86.
16. Ashfaq UA, Yousaf MZ, Aslam M, Ejaz R, Jahan S, Ullah O. siRNAs: potential therapeutic agents against hepatitis C virus. Virol J. 2011;8:276.
17. Morrissey DV, Lockridge JA, Shaw L, etal. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005;23:1002-1007.
18. DiFiglia M, Sena-Esteves M, Chase K, etal. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A. 2007;104:17204-17209.
19. Farah MH. RNAi silencing in mouse models of neurodegenerative diseases. Curr Drug Deliv. 2007;4:161-167.
20. Li T, Koshy S, Folkesson HG. RNA interference for CFTR attenuates lung fluid absorption at birth in rats. Respir Res. 2008;9:55.
21. Courties G, Presumey J, Duroux-Richard I, Jorgensen C, Apparailly F. RNA interference-based gene therapy for successful treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2009;9:535-538.
22. Martinez LA, Naguibneva I, Lehrmann H, etal. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A. 2002;99:14849-14854.
23. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. Prospects of RNA interference therapy for cancer. Gene Ther. 2006;13:464-477.
24. Takeshita T, Ochiya T. Therapeutic potential of RNA interference against cancer. Cancer Sci. 2006;97:689-696.
25. Whelan J. First clinical data on RNAi. Drug Discov Today. 2005;10:1014-1015.
26. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009;457:426-433.
27. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2011;11:59-67.
28. Davis ME, Zuckerman JE, Choi CH, etal. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464:1067-1070.
29. Hammond SM. Dicing and slicing the core machinery of the RNA interference pathway. FEBS Lett. 2005;579:5822-5829.
30. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell. 2005;123:607-620.
31. Tolia NH, Joshua-Tor L. Slicer and the Argonautes. Nat Chem Biol. 2007;3:36-43.
32. Ameres SL, Martinez J, Schroeder R. Molecular basis for target RNA recognition and cleavage by human RISC. Cell. 2007;130:101-112.
33. Rand TA, Petersen S, Du F, Wang X. Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell. 2005;123:621-629.
34. Dykxhoorn DM, Lieberman J. Knocking down disease with siRNAs. Cell. 2006;126:231-235.
35. Novina CD, Sharp PA. The RNAi revolution. Nature. 2004;430:161-164.
36. Lingel A, Sattler M. Novel modes of protein-RNA recognition in the RNAi pathway. Curr Opin Struct Biol. 2005;15:107-115.
37. Bartlett DW, Davis ME. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 2006;34:322-333.
38. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9: 775-789.
39. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296:550-553.
40. Röther S, Meister G. Small RNAs derived from longer non-coding RNAs. Biochimie. 2011;93:1905-1915.
41. Ghildiyal M, Zamore PD. Small silencing RNAs: an expanding universe. Nat Rev Genet. 2009;10:94-108.
42. Yu B, Zhao X, Lee LJ, Lee RJ. Targeted delivery Systems for oligonucleotide therapeutics. AAPS J. 2009;11:195-203.
43. Chen SH, Zhaori G. Potential clinical applications of siRNA technique: benefits and limitations. Eur J Clin Invest. 2011;41:221-232.
44. Masiero M, Nardo G, Indraccolo S, Favaro E. RNA interference: implications for cancer treatment. Mol Aspects Med. 2007;1:143-166.
45. Baker M. Homing in on delivery. Nature. 2010;462:1225-1228.
46. De Smaele E, Ferretti E, Gulino A. MicroRNAs as biomarkers for CNS cancer and other disorders. Brain Res. 2010;1338:100-111.
47. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev. 2007;59:75-86.
48. Zhao X, Pan F, Holt CM, Lewis AL, Lu JR. Controlled delivery of antisense oligonucleotides: a brief review of current strategies. Expert Opin Drug Deliv. 2009;6:673-686.
49. Bumcrot D, Manoharan M, Koteliansky V, Sah DWY. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol. 2006;2:711-719.
50. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;2:129-138.
51. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007;3:173-184.
52. Heidel JD, Yu Z, Liu JY, etal. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunitM2siRNA. Proc Natl Acad Sci U S A. 2007;104:5715-5721.
53. Desai AA, Schilsky RL, Young A, etal. A phase I study of antisense oligonucleotide GTI-2040given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol. 2005;6:958-965.
54. Grimm D, Streetz KL, Jopling CL, etal. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006;441:537-541.
55. Castanotto D, Sakurai K, Lingeman R, etal. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res. 2007;35:5154-5164.
56. Hornung V, Guenthner-Biller M, Bourquin C, etal. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med. 2005;11:263-270.
57. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol. 2005;23:457-462.
58. Gantier MP, Williams BR. The response of mammalian cells to double-stranded RNA. Cytokine Growth Factor Rev. 2007;18:363-371.
59. Kleinman ME, Yamada K, Takeda A, etal. Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008;452:591-597.
60. Jackson AL, Bartz SR, Schelter J, etal. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol. 2003;21:635-637.
61. Jackson AL, Burchard J, Schelter J, etal. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA. 2006;12:1179-1187.
62. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther. 2002;1:347-355.
63. Oliveira S, van Rooy I, Kranenburg O, Storm G, Schiffelers R. Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes. Int J Pharm. 2007;331:211-214.
64. Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG. Lipid-based nanotherapeutics for siRNA delivery. J Intern Med. 2010;267:9-21.
65. Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine. 2009;4:99-105.
66. De Angelis F, Gentile F, Mecarini F, etal. Breaking the diffusion limit with super-hydrophobic delivery of molecules to plasmonic nanofocusing SERS structures. Nat Photonics. 2011;5:682-687.
67. Pujia A, De Angelis F, Scumaci D, etal. Highly efficient human serum filtration with water-soluble nanoporous nanoparticles. Int J Nanomedicine. 2010;5:1005-1015.
68. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3:16-20.
69. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5:61-71.
70. Wong MS. Nanoparticles and catalysis. In: Didier Astruc, editor. Angewandte Chemie International Edition. Weindham, Germany: Wiley; 2008.
71. Knöpfel T, Akemann W. Nanobiotechnology: remote control of cells. Nat Nanotechnol. 2010;8:560-561.
72. Michalet X, Pinaud FF, Bentolila LA, etal. Quantum dots for live cells, in vivo imaging, and diagnostics. Science. 2005;307:538-544.
73. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5:505-515.
74. Glass G. Pharmaceutical patent challenges-time for reassessment? Nat Rev Drug Discov. 2004;3:1057-1062.
75. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarrier as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751-760.
76. Weisleder R, Kimberly K, Yi Sun E, Shtaland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol. 2005;23:1418-1423.
77. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60:1615-1626.
78. Park Ji-Ho, Gu L, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ. Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat Mater. 2009;8:331-336.
79. Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev. 2010;62:1052-1063.
80. Tasciotti E, Liu X, Bhavane R, etal. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic application. Nat Nanotechnol. 2008;3:152-157.
81. Chan JM, Zhang L, Tong, etal. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci U S A. 2010;107:2213-2218.
82. Sengupta S, Eavarone D, Capila I, etal. Temporal targeting of tumor cells and neovasculature with a nanoscale delivery system. Nature. 2005;436:568-572.
83. Bigall NC, Curcio A, Pernia Leal MP, etal. Magnetic nanocarriers with tunable pH dependence for controlled loading and release of cationic and anionic payloads. Adv Mater. 2011;23:5645-5650.
84. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet. 2007;8:573-587.
85. Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem Rev. 2009;109:259-302.
86. Gao Y, Liu XL, Li XR. Research progress on siRNA delivery with nonviral carriers. Int J Nanomedicine. 2011;6:1017-1025.
87. Kim WJ, Kim SW. Efficient siRNA delivery with non-viral polymeric vehicles. Pharm Res. 2009;26:657-666.
88. Schaffert D, Wagner E. Gene therapy progress and prospects: synthetic polymer-based systems. Gene Ther. 2008;15:1131-1138.
89. Tokatlian T, Segura T. siRNA applications in nanomedicine. Nanomed Nanobiotechnol. 2010;2:305-315.
90. Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA. 2003;9:1034-1048.
91. Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther. 2006;13:644-670.
92. Malik R, Roy L. Design and development of antisense drugs. Exp Opin Drug Discov. 2008;3:1189-1207.
93. Chiarantini L, Cerasi A, Fraternale A, etal. Comparison of a novel delivery system for antisense peptide nucleid acids. J Control Release. 2005;109:24-36.
94. Soutschek J, Akinc A, Bramlage B, etal. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432:173-178.
95. Raal FD, Santos RD, Blom DJ, etal. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998-1006.
96. Zhao X, Li H, Lee JR. Targeted drug delivery via folate receptors. Expert Opin Drug Deliv. 2008;5:309-319.
97. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 2005;65:8984-8992.
98. Song E, Zhu P, Lee SK, etal. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005;23:709-717.
99. McNamara JO 2nd, Andrechek ER, Wang Y, etal. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol. 2006;24:1005-1015.
100. Muratovska A, Eccles MR. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. 2004;558:63-68.
101. Hatakeyama H, Ito E, Akita H, etal. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. J Control Release. 2009;139:127-132.
102. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A. 2007;104:15549-15554.
103. Pirollo KF, Chang EH. Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res. 2008;68:1247-1250.
104. Lee H, Mok H, Lee S, Oh YK, Park TG. Target specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. J Control Release. 2007;119:245-252.
105. Rozema DB, Lewis DL, Wakefield DH, etal. Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A. 2007;104:12982-12987.
106. Zuhorn IS, Engberts JB, Hoeckstra D. Gene delivery by cationic lipid vectors: overcoming cellular barriers. Eur Biophys J. 2007;36:349-362.
107. Chirila TV, Rakoczy PE, Garrett KL, Lou X, Constable IJ. The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides. Biomaterials. 2002;23:321-342.
108. Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AK, Han MS, Mirkin CA. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science. 2006;312:1027-1030.
109. Convertine AJ, Benoit DS, Duvall CL, Hoffman AS, Stayton PS. Development of a novel endosomolytic diblock copolymer for siRNA delivery. J Control Release. 2009;133:221-229.
110. Wagner E. Polymers for siRNA delivery: inspired by viruses to be targeted, dynamic, and precise. Acc. Chem. Res. 2011;22: DOI: 10.1021/ar2002232.
111. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 2005;12:461-466.
112. Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev. 2009;61:850-862.
113. Nimesh S, Gupta N, Chandra R. Cationic polymer based nanocarriers for delivery of therapeutic nucleic acids. J Biomed Nanotechnol. 2011;7:504-520.
114. Singha K, Namgung R, Kim WJ. Polymers in small-interfering RNA delivery. Nucleic Acid Ther. 2011;21:133-147.
115. Troiber C, Wagner E. Nucleic acid carriers based on precise polymer conjugates. Bioconjug Chem. 2011;22:1737-1752.
116. Duncan R. Polymer therapeutics as nanomedicines: new perspectives. Curr Opin Biotechnol. 2011;22:492-501.
117. Semple SC, Akinc A, Chen J, etal. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28:172-176.
118. Guo P, Coban O, Snead NM, etal. Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev. 2010;62:650-666.
119. Merritt WM, Lin YG, Spannuth WA, etal. Effect of interleukin-8gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst. 2008;100:359-372.
120. Landen CN Jr, Chavez-Reyes A, Bucana C, etal. Therapeutic EphA2gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005;65:6910-6918.
121. Dharmapuri S, Peruzzi D, Marra E, etal. Intratumor RNA interference of cell cycle genes slows down tumor progression. Gene Ther. 2011;18:727-733.
122. Ma Z, Li J, He F, Wilson A, Pitt B, Li S. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem Biophys Res Commun. 2005;330:755-759.
123. Dokka S, Toledo D, Shi X, Castranova V, Rojanasakul Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm Res. 2000;17:52152-52155.
124. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165-196.
125. Gallarate M, Battaglia L, Peira E, Trotta M. Peptide-loaded solid lipid nanoparticles prepared through coacervation technique. International Journal of Chemical Engineering. 2011;1-6.
126. Geisbert TW, Lee AC, Robbins M, etal. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010;375:1896-1905.
127. Lobovkina T, Jacobson GB, Gonzalez-Gonzalez E, etal. In vivo sustained release of siRNA from solid lipid nanoparticles. ACS Nano. 2011;5:9977-9983.
128. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Control Release. 2006;116:1239.
129. Boussif O, Lezoualc'h F, Zanta MA, etal. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A. 1995;92:7297-7301.
130. Zimmermann TS, Lee ACH, Akinc A, etal. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441:111-114.
131. Akinc A, Goldberg M, Qin J, etal. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther. 2009;17:872-879.
132. Akinc A, Zumbuehl A, Goldberg M, etal. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol. 2008;26:561-569.
133. Vaishnaw AK, Gollob J, Gamba-Vitalo C, etal. A status report on RNAi therapeutics. Silence. 2010;1:14.
134. Chen AA, Derfus AM, Khetani SR, Bhatia SN. Quantum dots to monitor RNAi delivery and improve gene silencing. Nucleic Acids Res. 2005;33:190.
135. Gao X, Cui Y, Levenson RM, Chung LWK, Nie1 S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 2004;22:969-976.
136. Yezhelyev MV, Qi L, O'Regan RM, Nie S, Gao X. Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging. J Am Chem Soc. 2008;130:9006-9012.
137. Oishi M, Nakaogami J, Ishii T, Nagasaki Y. Smart PEGylated gold nanoparticles for the cytoplasmic delivery of siRNA to induce enhanced gene silencing Chem. Lett. 2006;35:1046-1047
138. Elbakry A, Zaky A, Liebl R, Rachel R, Goepferich A, Breunig M. Layer-by-layer assembled gold nanoparticles for siRNA delivery. Nano Lett. 2009;5:2059-2064.
139. Lee JS, Green JJ, Love KT, Sunshine J, Langer R, Anderson DG. Gold, poly(beta-amino ester) nanoparticles for small interfering RNA delivery. Nano Lett. 2009;6:2402-2406.
140. Lytton-Jean A, Langer R, Anderson DG. Five years of siRNA delivery: spotlight on gold nanoparticles. Small. 2011;7:1932-1937.
141. Medarova Z, Pham W, Farrar C, Petkova V, Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med. 2007;3:372-377.
142. Curcio A, Marotta R, Riedinger A, Palumberi D, Falqui A, Pellegrino T. Magnetic pH-responsive nanogels as multifunctional delivery tools for small interfering RNA (siRNA) and iron oxide nanoparticles (IONPs). Chem Commun (Camb). 2012;48:2400-2402.
143. Xia T, Kovochich M, Liong M, etal. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano. 2009;3:3273-3286.
144. Tanaka T, Mangala LS, Vivas-Mejia PE, etal. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010;70:3687-3696.
145. Kam NW, Liu Z, Dai H. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J Am Chem Soc. 2005;127:12492-12493.
146. Lee S, Yang SC, Kao CY, Pierce RH, Murthy N. Solid polymeric microparticles enhance the delivery of siRNA to macrophages in vivo. Nucleic Acids Res. 2009;37:145.
147. Jacobson GB, Shinde R, McCullough RL, etal. Nanoparticle formation of organic compounds with retained biological activity. J Pharm Sci. 2010;99:2750-2755.
148. Krebs MD, Jeon O, Alsberg E. Localized and sustained delivery of silencing RNA from macroscopic biopolymer hydrogels. J Am Chem Soc. 2009;131:9204-9206.
149. Patil Y, Panyam J. Polymeric nanoparticles for siRNA delivery and gene silencing. Int J Pharm. 2009;367:195-203.
150. Yagi N, Manabe I, Tottori T, etal. A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo. Cancer Res. 2009;69:6531-6538.
151. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9:615-627.
152. Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond). 2008;5:703-717.
153. Decuzzi P, Causa F, Ferrari M, Netti PA. The effective dispersion of nanovectors within the tumor microvasculature. Ann Biomed Eng. 2006;4:633-641.
154. Li L, Wilcox D, Zhao X, etal. Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery. Gene Ther. 2011;1-6.
155. Dominska M, Dykxhoorn DM. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci. 2010;123:1183-1189.
156. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm. 2008;4:487-495.
157. Seyhan AA. RNAi: a potential new class of therapeutic for human genetic disease. Hum Genet. 2011;130:583-605.
158. Davidson BL, McCray PB. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011;12:329-340.
159. Alnylam Pharmaceuticals. Alnylam achieves first human proof of concept for an RNAi therapeutic with GEMINI study. Available from: http://www.alnylam.com/Programs-and-Pipeline/Partner-Programs/index.php. Accessed April 17, 2012.
160. Leachman SA, Hickerson RP, Hull PR, etal. Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. J Dermatol Sci. 2008;51:151-157.
161. Leachman SA, Hickerson RP, Schwarz ME, etal. First-in-human mutation targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther. 2010;18:442-446.
162. Gondi C, Rao JS. Concepts in in-vivo siRNA delivery for cancer therapy. J Cell Physiol. 2009;220:285-291.
163. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug resistant, BCR-ABL1+ leukemia cells. Nat Med. 2004;10:1187-1189.
164. Koldehoff M, Steckel NK, Beelen DW, Elmaagacli AH. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med. 2007;7:47-55.
165. Shim MS, Kwon YJ. Efficient and targeted delivery of siRNA in-vivo. FEBS J. 2010;277:4814-4817.
166. Vaccari L, Canton D, Zaffaroni N, et al. Porous silicon as drug carrier for controlled delivery of doxorubicin anticancer agent. Micr. Eng. 2006;83:1598-1601.
167. Gentile F, Tirinato L, Battista E, et al. Cells preferentially grow on rough substrates. Biomaterials. 2010;31:7205-7212.
168. Gaspari M, Ming-Cheng Cheng M, Terracciano R, et al. Nanoporous surfaces as harvesting agents for mass spectrometric analysis of peptides in human plasma. J Proteome Res. 2006;5:1261-1266.